Hence, its role in predicting response to immune checkpoint blockade needs to be further evaluated, and further research is needed to assess the efficacy of IL-1β inhibitors with immunotherapy or other anti-cancer therapeutic agents [37]. The gene discussed is IL1B; the disease is cancer.